RNF43

RNF43

RNF43 Overview

Molecule Name
E3 ubiquitin-protein ligase RNF43
Drug Development Progress
Drugs in Clinical Trials1
Approved Drugs0
Highest Development StagePhase 1 Clinical
Target Synonym
Background
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signaling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled. Acts on both canonical and non-canonical Wnt signaling pathway. Along with RSPO2 and ZNRF3, constitutes a master switch that governs limb specification (By similarity)

RNF43 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SZN-043SZN-043; SWEETS-1Phase 1 ClinicalSurrozen Inc
Hepatitis, Alcoholic; Liver Cirrhosis
Details